Ayse Tana Aslan

Ayse Tana Aslan

Auto-generated profile, based on publicly available information

Ayse Tana Aslan

Division of Pediatric Pulmonology, Faculty of Medicine, Gazi University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in Thorax
Verified
Journal Article
Open access
PDF file
CKCarolin Kröner
Carolin Kröner
TWThomas Wittmann
Thomas Wittmann
SRSimone Reu
Simone Reu
VTVeronika Teusch
Veronika Teusch
MKMathias Klemme
Mathias Klemme
MGMatthias Griese
Matthias Griese
Background Knowledge about the clinical spectrum of lung disease caused by variations in the ATP binding cassette subfamily A member 3 (ABCA3) gene is limited. Here we describe genotype-phenotype correlations in a European cohort. Methods We retrospectively analysed baseline and outcome characteristics of 40 patients with two disease-causing ABCA3 mutations collected between 2001 and 2015. Results Of 22 homozygous (15 male) and 18 compound heterozygous patients (3 male), 37 presented with neonatal respiratory distress syndrome as term babies. At follow-up, two major phenotypes are documented: patients with (1) early lethal mutations subdivided into (1a) dying within the first 6 months or (1b) before the age of 5 years, and (2) patients with prolonged survival into childhood, adolescence or adulthood. Patients with null/null mutations predicting complete ABCA3 deficiency died within the 1st weeks to months of life, while those with null/other or other/other mutations had a more variable presentation and outcome. Treatment with exogenous surfactant, systemic steroids, hydroxychloroquine and whole lung lavages had apparent but many times transient effects in individual subjects. Conclusions Overall long-term (>5 years) survival of subjects with two disease-causing ABCA3 mutations was <20%. Response to therapies needs to be ascertained in randomised controlled trials.

5 February 2015 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CKCarolin Kröner
Carolin Kröner
SRSimone Reu
Simone Reu
VTVeronika Teusch
Veronika Teusch
ASAndrea Schams
Andrea Schams
AGAnn-Christin Grimmelt
Ann-Christin Grimmelt
MGMatthias Griese
Matthias Griese
Patients with interstitial lung disease due to surfactant protein C (SFTPC) mutations are rare and not well characterised.We report on all subjects collected over a 15-year period in the kids-lung register with interstitial lung disease and a provenSFTPCmutation. We analysed clinical courses, interventions and outcomes, as well as histopathological and radiological interrelations.17 patients (seven male) were followed over a median of 3 years (range 0.3–19). All patients were heterozygous carriers of autosomal dominantSFTPCmutations. Three mutations (p.L101P, p.E191 K and p.E191*) have not been described before in the context of surfactant protein C deficiency. Patients with alterations in the BRICHOS domain of the protein (amino acids 94–197) presented earlier. At follow-up, one patient was healthy (2 years), six patients were “sick-better” (2.8 years, range 0.8–19), seven patients were “sick-same” (6.5 years, 1.3–15.8) and three patients were “sick-worse” (0.3 years, 0.3–16.9). Radiological findings changed from ground-glass to increasing signs of fibrosis and cyst formation with increasing age. Empiric treatments had variable effects, also in patients with the same genotype.Prospective studies with randomised interventions are urgently needed and can best be performed in the framework of international registers.

12 June 2020 in Pediatric Pulmonology
Verified
Journal Article
Open access
PDF file
BSBurcu Pınar Senkalfa
Burcu Pınar Senkalfa
AAAyse Tana Aslan
Ayse Tana Aslan
AAAyse T. Aslan
Ayse T. Aslan
TGTugba Ramaslı Gursoy
Tugba Ramaslı Gursoy
ASAzime S. Soysal
Azime S. Soysal
MIMustafa N. İlHan
Mustafa N. İlHan
Background: We aimed to evaluate anxiety among children with cystic fibrosis (CF) and their mothers related to the COVID‐19 pandemic.Methods: A total of 45 patients with CF and their mothers were enrolled in the study together with 90 age‐matched healthy children and their mothers as a control group. The State and Trait Anxiety Inventory (STAI) was administered by teleconference with children aged 13 to 18 years old and their mothers. The STAI for children was administered with children aged 9 to 12 years. Results were compared with age‐matched healthy children and their mothers. The relationship between anxiety scores of children with CF and their mothers was evaluated by comparing with clinical data of children with CF. At the conclusion of the teleconference, mothers were asked whether their anxiety had changed as a result of the interview.Results: It was found that healthy children aged 13 to 18 years had higher state anxiety scores than age‐matched children with CF. Mothers of children with CF had higher trait anxiety scores, especially those of children aged 0 to 12 years, than mothers of healthy children (P < .05). For mothers of children with CF, state anxiety scores were higher among those whose children had chronic Pseudomonas infection (P < .05). Most mothers of children with CF stated that their anxiety decreased following the interview.Conclusion: The COVID‐19 pandemic may increase anxiety among mothers of children with CF as well those with healthy children. However, COVID‐19 had no effect on the anxiety of children with CF. Informing parents of children with CF about COVID‐19 by teleconference may decrease anxiety.

11 November 2019 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DDDeniz Dogru
Deniz Dogru
ECErkan Cakir
Erkan Cakir
AAAyse Tana Aslan
Ayse Tana Aslan
Nazan CobanogluNazan Cobanoglu
Nazan Cobanoglu
SPSevgi Pekcan
Sevgi Pekcan
UÖUğur Özçelik
Uğur Özçelik

1 February 2003 in Pediatric Neurology
Verified
Journal Article
Closed access
DADidem Aliefendioğlu
Didem Aliefendioğlu
AAA.YŞe Tana Aslan
A.YŞe Tana Aslan
TCTurgay Coşkun
Turgay Coşkun
ADAli Dursun
Ali Dursun
FÇFatma Nur Çakmak
Fatma Nur Çakmak
MKMehmet Kesimer
Mehmet Kesimer

1 November 2005 in Clinical Pediatrics
Verified
Journal Article
Closed access
EYEbru Yalçın
Ebru Yalçın
DDDeniz Doğru
Deniz Doğru
UÖUğur Özçelik
Uğur Özçelik
NKNural Kiper
Nural Kiper
AAAyşe Tana Aslan
Ayşe Tana Aslan
AGAhmet Gözaçan
Ahmet Gözaçan
We reviewed our experience on tracheomalacia (TM) and bronchomalacia (BM) in children who presented with chronic respiratory problems and evaluated their clinical and radiologic characteristics and their associations with other disorders. There were 26 males and 8 females with a median age of 9 months. The main symptoms were wheezing, persistent or recurrent pneumonia, and chronic cough. Atelectasis on chest radiograph was the most common sign. Of 23 children with TM, 1 had a double aortic arch, 1 had tracheoesophageal fistula, and 1 other had associated laryngomalacia. BM was found in 27 children and was predominantly seen on the right side. TBM was found in 16 cases (in an infant TBM was accompanied by pharyngeal dyskinesia and in another by laryngomalacia). Malacia disorders were associated with gastroesophageal reflux, cardiovascular anomalies, and tracheoeosophageal fistula. TM and BM should be considered in the differential diagnosis of children with chronic and recurrent respiratory symptoms. Early diagnosis of malacia disorders will prevent unnecessary use of antibiotics or antiasthmatic drugs, which are often abused to treat these children. In these patients, treatment for associated diseases should also be considered.